Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410344 | 1.00 | GAA (0.40) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL18531736 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL15007192 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL19215849 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL15007184 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL1265760 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL14856082 | 0.87 | MTNR1A (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL25259047 | 0.85 | TLR9 (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL16645216 | 0.85 | TLR9 (0.41) | GAALMNAMTNR1AMTNR1BTLR9 | |
| SCHEMBL25587333 | 0.83 | CCR2 (0.39) | LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| EP-4208448-B1 | ACRYLAMIDE DERIVATIVES | NRG THERAPEUTICS LTD (GB) | 2025-04-23 | — | — | EP | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| EP-4208448-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096712-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-7772221-B2 | Diaminopropane derived macrocycles as inhibitors of β amyloid production | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, BACE2 | GAA 418/4885LMNA 489/4885MTNR1A 3729/4885 |
| US-20230312466-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | GAA 1249/4885LMNA 3307/4885MTNR1A 1529/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | GAA 3295/4885LMNA 1162/4885MTNR1A 3685/4885 |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | APP, BACE1, PSEN1 | GAA 463/4885LMNA 293/4885MTNR1A 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.